新辅助免疫治疗后减少瘤床检查仍可准确评估病理缓解
本研究基于134例可手术切除的IIIB/C/D期黑色素瘤患者标本,评估新辅助伊匹木单抗联合纳武利尤单抗后减少瘤床检查对%RVT计算准确性的影响。七种改良方案均显示%RVT计算准确性优异(R²>0.97),六种方案对MPR/非MPR分类准确性≥96%。建议淋巴结≤3cm全部取材、>3cm取至少一个完整横截面,切片上限20张仍保持93%准确性。
要点
- 减少瘤床检查不影响%RVT计算准确性,R²>0.97
- 切片上限20张时%RVT计算仍保持93%准确
- 推荐淋巴结≤3cm全部取材、>3cm取完整横截面
核心结论
- 新辅助IIIB/C/D期黑色素瘤标本可减少瘤床包埋检查而不显著影响%RVT计算准确性。
- 推荐更新病理评估方案:淋巴结≤3cm全部取材,>3cm取至少一个完整横截面切片,切片上限20张。
研究设计与样本
- 对134例新辅助伊匹木单抗联合纳武利尤单抗治疗后标本进行全面的组织病理学检查。
- 用七种改良方案重新计算每例%RVT并与INMC方案比较,另通过随机抽取50%、33%、25%瘤床切片进行模拟研究。
主要发现
- 所有改良方案%RVT准确性优异(R²>0.97),五种方案准确性>90%。
- 六种方案对MPR/非MPR及病理缓解分类准确性≥96%。
- 每标本平均检查切片数减少9%至58%。
- 检查50%、33%、25%瘤床切片时,分别有85%、79%、74%的模拟%RVT计算与INMC计算相差在5%以内。
- 切片检查上限为20张时,%RVT计算仍保持93%准确。
关键数值与推荐
- 淋巴结≤3cm应全部取材检查。
- 肉眼受累淋巴结>3cm应采用改良检查方案,至少取一个完整横截面 transverse slice。
- 瘤床切片检查上限设为20张是合理的。
临床怎么用
- 病理科可按推荐方案减少新辅助黑色素瘤标本瘤床切片数量,仍可准确计算%RVT并分类病理缓解。
- 对≤3cm淋巴结全部取材、>3cm淋巴结取完整横截面,切片上限20张,有助于在保证准确性的同时减少工作量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant immunotherapy produces event-free survival advantage over adjuvant therapy for patients with surgically resectable macroscopic stage IIIB/C/D melanoma. Pathological response, determined as percentage residual viable tumor (% RVT), provides critical prognostic information and informs management decisions. Here, we assessed accuracy of %RVT calculation when reduced tumor bed (TB) was examined and leverage these results proposing streamlined protocols for pathological examination. PATIENTS AND METHODS: Comprehensive histopathological examination was carried out on 134 patient specimens after neoadjuvant immunotherapy with ipilimumab and nivolumab. Impact on %RVT when evaluating less TB than recommended by the initial International Neoadjuvant Melanoma Consortium (INMC) protocol was assessed. Firstly, % RVT of each case was recalculated using seven modified protocols and compared with % RVT obtained under INMC protocol. Next, a simulation study was carried out recalculating % RVT by random sampling 50%, 33%, and 25% of TB slides per specimen. RESULTS: There was excellent accuracy in %RVT (R2 > 0.97) for all the modified protocols and >90% accuracy in five protocols. Accuracy of major pathological response (MPR)/non-MPR and pathological response category classification was ≥96% in six protocols. The decrease in average slides examined per specimen ranged from 9% to 58%. In total, 85%, 79%, and 74% of simulations recalculating %RVT were within 5% of the INMC calculation when 50%, 33%, and 25% of TB slides were examined, respectively. If TB slide examination is capped at 20, %RVT calculation remains 93% accurate. CONCLUSIONS: TB embedded for histopathological examination in neoadjuvant stage IIIB/C/D melanoma specimens can be reduced without significantly compromising accuracy of %RVT calculation. We recommend an updated pathological assessment protocol: lymph nodes ≤3 cm examined in entirety; macroscopically involved lymph nodes >3 cm should have a modified examination protocol of at least a full cross-sectional transverse slice. Capping TB slides examined at 20 appears reasonable. This refined approach results in high accuracy and significant reduction in the slides examined.
引用
- Rawson RV, Maher NG, Menzies AM, et al. Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma. Ann Oncol. 2025. PMID: 41183783. doi:10.1016/j.annonc.2025.10.1237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。